Novo Nordisk Invests 13 Billion SEK in New Factory in Odense
2024-12-16
TT Nyhetsbyrån
Danish pharmaceutical giant Novo Nordisk, a world leader in weight loss medication, is investing 8.5 billion DKK (approximately 13 billion SEK) in a new factory in Odense. This significant investment will enhance the company's production capacity and further solidify its position in the global market. Novo Nordisk's new factory will focus on manufacturing innovative medications, including diabetes treatments and obesity drugs. With this expansion, the company aims to meet the growing demand for its products and improve the lives of millions of people worldwide. By leveraging its expertise in pharmaceutical manufacturing, Novo Nordisk is poised for continued success.